About BioSpecifics Technologies
BioSpecifics Technologies is a Healthcare company based in Lynbrook (United States) founded in 1957, and was acquired by Endo International in October 2020. Injectable collagenase is developed for multiple medical indications. Its focus areas include Diversified Pharmaceuticals.
Company details
BioSpecifics Technologies is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. It claims to have clinically tested for 12 indications and is being marketed as XIAFLEX for indications, such as Dupuytrens contracture and Peyronies disease. It is internally working on the indications such as Human Lipoma, Uterine Fibroids and Capsular contracture of breast. Its partner Endo is handling the RD for the indications which include frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and uterine fibroids.
- Headquarters Lynbrook, United States
- Stage Acquired
- SectorsHealthcare
- Website biospecifics.com
- Social X
- Acquired by Endo International (Oct 2020)
- Investors
- Acquired byEndo International
(Oct 2020)
Investors in BioSpecifics Technologies
BioSpecifics Technologies has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Endo International.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Global pharmaceutical company manufacturing branded, generic formulations, and OTC medicines | 1997 | endo.com | Malvern, United States |
Investor details for BioSpecifics Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BioSpecifics Technologies
182 people are tracked at BioSpecifics Technologies (68 in leadership, 7 in board & advisors, 107 in team).
| Name | Role | Group |
|---|---|---|
Michael Randolph | Global Head, Manufacturing Operations | Leadership |
Blaise Coleman | President & CEO | Leadership |
Joan Ramella | Associate Director Clinical Operations | Leadership |
Mick McGuinness | Global Head, Quality & Compliance | Leadership |
Matthew J. Maletta | EVP & Chief Legal Officer | Leadership |
Tracy Basso | Chief Human Resources Officer | Leadership |
Karen Giandonato | Sr. Director, Corporate HR Operations | Leadership |
James Papp | Head, Endo Ventures Limited & SVP of Global Supply Chain | Leadership |
Cheryl Stouch | SVP, Information Technology & Chief Information Officer | Leadership |
Patrick Barry | EVP & Chief Commercial Officer | Leadership |
Richard Hooper | Director Strategic Sourcing | Leadership |
Heath Weber | Director, Web Center Of Excellence | Leadership |
Melvin Prasad | National Sales Director | Leadership |
Phillip Wydro | Executive Director - IT Enterprise ERP & Finance | Leadership |
Maritza Russo | Associate Director, Talent Acquisition | Leadership |
Tim Garrett | A. Director, Managed Care | Leadership |
Dayna Sracic | Executive Director, Consumer Marketing | Leadership |
David Hughes | Associate Director Global Quality Systems | Leadership |
Susan Williamson | SVP & Chief Compliance Officer | Leadership |
Lou Donato | Executive Director, Corporate Compliance | Leadership |
162 more people are available in the full profile.
Complete people profiles for BioSpecifics Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of BioSpecifics Technologies
3 dated milestones of BioSpecifics Technologies across 63 years, from founding to its latest funding, stage changes and deals.
- Founded BioSpecifics Technologies is founded.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Endo International.
Web traffic of BioSpecifics Technologies
Websites that share an audience with BioSpecifics Technologies (biospecifics.com).
Websites whose visitors overlap most with BioSpecifics Technologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
ieb.fr | ieb.fr | 100% | – | ||
| renovo.com | 100% | View details | |||
| stiefel.com | 100% | View details | |||
| fibrogen.com | 100% | 6.2K | #2,827,257 | View details | |
lipomaboard.com | lipomaboard.com | 73% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for BioSpecifics Technologies
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as BioSpecifics Technologies (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biospecifics Technologies
Complete news archive for BioSpecifics Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioSpecifics Technologies
BioSpecifics Technologies was founded in 1957.
BioSpecifics Technologies is headquartered in Lynbrook, United States. It is registered at Lynbrook, New York, United States.
BioSpecifics Technologies is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. It claims to have clinically tested for 12 indications and is being marketed as XIAFLEX for indications, such as Dupuytrens contracture and Peyronies disease. It is internally working on the indications such as Human Lipoma, Uterine Fibroids and Capsular contracture of breast. Its partner Endo is handling the RD for the indications which include frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and uterine fibroids.
BioSpecifics Technologies has 1 investor. Key investors include Endo International.
Yes. BioSpecifics Technologies was acquired by Endo International in October 2020.